[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100518507":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":37,"locations":45,"responsibleParty":222,"collaborators":25,"id":224,"slug":225,"hasResults":226,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":25,"eligibilityCriteria":230,"healthyVolunteers":226,"sex":231,"minAge":232,"maxAge":25,"enrollmentInfo":233,"targetDuration":25,"studyType":236,"phases":237,"briefSummary":239,"conditions":240,"keywords":25,"overallStatus":48,"whyStopped":25,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},{"fullName":5,"class":6},"Genentech, Inc.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation Cohort","EXPERIMENTAL","Participants in successive cohorts will receive escalating doses of RO7566802, as an intravenous (IV) infusion on Day 1 of each 21-day cycle followed by RO7566802 in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.",[13,14],"Drug: RO7566802","Drug: Atezolizumab",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion Cohort","Participants with select solid tumors will receive a recommended dose of RO7566802, determined in Dose Escalation phase, as an IV infusion in combination with a fixed dose of atezolizumab, as an IV infusion on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","RO7566802","RO7566802 solution for infusion will be administered as specified in each treatment arm.",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Atezolizumab","Atezolizumab solution for infusion will be administered as specified in each treatment arm.",[9,16],[31],"Tecentriq®",[33],{"name":34,"affiliation":35,"role":36},"Clinical Trials","Hoffmann-La Roche","STUDY_DIRECTOR",[38,43],{"name":39,"role":40,"phone":41,"phoneExt":25,"email":42},"Reference Study ID Number: GO44431 https:\u002F\u002Fforpatients.roche.com\u002F","CONTACT","888-662-6728 (U.S. Only)","global-roche-genentech-trials@gene.com",{"name":44,"role":40,"phone":25,"phoneExt":25,"email":25},"Fastest response: use the inquiry form. No email attachments. https:\u002F\u002Fwww.gene.com\u002Fcontact-us\u002Fsubmit-medical-inquiry",[46,60,70,79,89,99,109,121,131,143,153,163,169,180,189,198,204,213],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":25},"University of Alabama at Birmingham (UAB)","RECRUITING","Birmingham","Alabama","35233","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-86.80249,33.52066,{"lat":58,"lon":57},{"facility":61,"status":48,"city":62,"state":63,"zip":64,"country":52,"countryCode":53,"cosmosGeoPoint":65,"geoPoint":69,"contacts":25},"Yale Cancer Center","New Haven","Connecticut","06520",{"type":55,"coordinates":66},[67,68],-72.92816,41.30815,{"lat":68,"lon":67},{"facility":71,"status":48,"city":72,"state":72,"zip":73,"country":52,"countryCode":53,"cosmosGeoPoint":74,"geoPoint":78,"contacts":25},"Icahn School of Medicine at Mount Sinai (ISMMS)","New York","10029",{"type":55,"coordinates":75},[76,77],-74.00597,40.71427,{"lat":77,"lon":76},{"facility":80,"status":48,"city":81,"state":82,"zip":83,"country":52,"countryCode":53,"cosmosGeoPoint":84,"geoPoint":88,"contacts":25},"The Ohio State University","Columbus","Ohio","43221-3502",{"type":55,"coordinates":85},[86,87],-82.99879,39.96118,{"lat":87,"lon":86},{"facility":90,"status":48,"city":91,"state":92,"zip":93,"country":52,"countryCode":53,"cosmosGeoPoint":94,"geoPoint":98,"contacts":25},"Magee-Woman's Hospital","Harrisburg","Pennsylvania","17109",{"type":55,"coordinates":95},[96,97],-76.88442,40.2737,{"lat":97,"lon":96},{"facility":100,"status":48,"city":101,"state":102,"zip":103,"country":52,"countryCode":53,"cosmosGeoPoint":104,"geoPoint":108,"contacts":25},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":55,"coordinates":105},[106,107],-86.78444,36.16589,{"lat":107,"lon":106},{"facility":110,"status":48,"city":111,"state":112,"zip":113,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":25},"St Vincent's Hospital Sydney","Darlinghurst","New South Wales","2010","Australia","AU",{"type":55,"coordinates":117},[118,119],151.21925,-33.87939,{"lat":119,"lon":118},{"facility":122,"status":48,"city":123,"state":124,"zip":125,"country":114,"countryCode":115,"cosmosGeoPoint":126,"geoPoint":130,"contacts":25},"Peter Maccallum Cancer Centre","Melbourne","Victoria","3000",{"type":55,"coordinates":127},[128,129],144.96332,-37.814,{"lat":129,"lon":128},{"facility":132,"status":48,"city":133,"state":134,"zip":135,"country":136,"countryCode":137,"cosmosGeoPoint":138,"geoPoint":142,"contacts":25},"British Columbia Cancer Agency - 600 10th Ave W","Vancouver","British Columbia","V5Z 4E6","Canada","CA",{"type":55,"coordinates":139},[140,141],-123.11934,49.24966,{"lat":141,"lon":140},{"facility":144,"status":48,"city":145,"state":146,"zip":147,"country":136,"countryCode":137,"cosmosGeoPoint":148,"geoPoint":152,"contacts":25},"Princess Margaret Cancer Centre","Toronto","Ontario","M5G 1Z5",{"type":55,"coordinates":149},[150,151],-79.39864,43.70643,{"lat":151,"lon":150},{"facility":154,"status":48,"city":155,"state":25,"zip":156,"country":155,"countryCode":157,"cosmosGeoPoint":158,"geoPoint":162,"contacts":25},"National University Hospital","Singapore","119074","SG",{"type":55,"coordinates":159},[160,161],103.85007,1.28967,{"lat":161,"lon":160},{"facility":164,"status":48,"city":155,"state":25,"zip":165,"country":155,"countryCode":157,"cosmosGeoPoint":166,"geoPoint":168,"contacts":25},"National Cancer Centre","168583",{"type":55,"coordinates":167},[160,161],{"lat":161,"lon":160},{"facility":170,"status":48,"city":171,"state":25,"zip":172,"country":173,"countryCode":174,"cosmosGeoPoint":175,"geoPoint":179,"contacts":25},"Addenbrooke's Hospital","Cambridge","CB2 0QQ","United Kingdom","UK",{"type":55,"coordinates":176},[177,178],0.11667,52.2,{"lat":178,"lon":177},{"facility":181,"status":48,"city":182,"state":25,"zip":183,"country":173,"countryCode":174,"cosmosGeoPoint":184,"geoPoint":188,"contacts":25},"Leicester Royal Infirmary","Leicester","LE1 5WW",{"type":55,"coordinates":185},[186,187],-1.13169,52.6386,{"lat":187,"lon":186},{"facility":190,"status":48,"city":191,"state":25,"zip":192,"country":173,"countryCode":174,"cosmosGeoPoint":193,"geoPoint":197,"contacts":25},"St Bartholomew's Hospital","London","EC1A 7BE",{"type":55,"coordinates":194},[195,196],-0.12574,51.50853,{"lat":196,"lon":195},{"facility":199,"status":48,"city":191,"state":25,"zip":200,"country":173,"countryCode":174,"cosmosGeoPoint":201,"geoPoint":203,"contacts":25},"Sarah Cannon Research Institute","W1G 6AD",{"type":55,"coordinates":202},[195,196],{"lat":196,"lon":195},{"facility":205,"status":48,"city":206,"state":25,"zip":207,"country":173,"countryCode":174,"cosmosGeoPoint":208,"geoPoint":212,"contacts":25},"Churchill Hospital","Oxford","OX3 7LJ",{"type":55,"coordinates":209},[210,211],-1.25596,51.75222,{"lat":211,"lon":210},{"facility":214,"status":48,"city":215,"state":25,"zip":216,"country":173,"countryCode":174,"cosmosGeoPoint":217,"geoPoint":221,"contacts":25},"The Royal Marsden hospital","Sutton","SM2 5PT",{"type":55,"coordinates":218},[219,220],-0.2,51.35,{"lat":220,"lon":219},{"type":223,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100518507","phase-1-a-study-to-evaluate-the-safety-pharmacokinetics-and-activity-of-ro7566802-as-a-single-agent-and-in-combination-with-atezolizumab-in-participants-with-locally-advanced-or-metastatic-solid-tumors-100518507",false,"NCT06031441","A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors","A Phase I, Open-Label, Multicenter, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* Life expectancy \\>=3 months, in the investigator's judgment\n* Adequate hematologic and end-organ function\n* Histologically confirmed locally advanced, recurrent, or metastatic incurable solid tumor malignancy that has progressed after available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care\n* Measurable disease per RECIST v1.1\n* Tumor specimen availability, for certain cohorts\n\nExclusion Criteria:\n\n* Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to Cycle 1 Day 1, with certain exceptions\n* Active hepatitis B or C\n* Active tuberculosis\n* Positive test for human immunodeficiency virus (HIV) infection\n* Administration of a live, attenuated vaccine (e.g., Flumist) within 4 weeks prior to RO7566802 infusion\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Active or history of autoimmune disease\n* Prior allogeneic stem cell or organ transplantation\n* Uncontrolled tumor-related pain\n* Significant cardiovascular disease\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":234,"type":235},250,"ESTIMATED","INTERVENTIONAL",[238],"PHASE1","This is a first-in-human Phase I, open-label, dose-escalation and expansion study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, pharmacodynamic, and preliminary anti-tumor activity of RO7566802 as a single agent and in combination with atezolizumab in participants with locally advanced, recurrent, or metastatic incurable solid tumor malignancies. Participants will be enrolled in 2 stages: dose escalation and expansion.",[241,242,243],"Locally Advanced Solid Tumors","Recurrent Solid Tumors","Metastatic Solid Tumors","2026-06-26",{"date":246,"type":247},"2026-06-29","ACTUAL",{"date":249,"type":247},"2023-11-27",{"date":251,"type":235},"2027-12-31",{"name":5,"class":6},18]